Slow released medicine containing antituberculotic

A technology for tuberculosis and sustained-release preparations, applied in the field of sustained-release injections and sustained-release implants, can solve the problems of difficulty in obtaining effective bactericidal concentration, side effects of increased doses, and unsatisfactory effects of multidrug-resistant tuberculosis

Inactive Publication Date: 2006-11-08
JINAN KANGQUAN PHARMA TECH
View PDF8 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, many new anti-tuberculosis drugs have shown good efficacy, but the effect on multidrug-resistant tuberculosis (MDR-TB) is not ideal
Because for many chronic lesions, especially local lesions, it is difficult to obtain an effective bactericidal concentration with the administration of conventional therapy
Increased dose or long-term use of drugs will have many side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Put 90, 90 and 80 mg of polystyrene (p-carboxyphenylpropane (p-CPP): sebacic acid (SA) 20:80) copolymer into (A), (B) and (C) three Then add 100 ml of dichloromethane to each container. After dissolving and mixing, add 10m cycloserine, 10mg ofloxacin, 10mg cycloserine and 10mg ofloxacin respectively, shake well and use spray drying method Prepare injection microspheres containing 10% cycloserine, 10% ofloxacin, 10% cycloserine and 10% ofloxacin. Then the microspheres were suspended in physiological saline containing 15% mannitol to prepare the corresponding suspension type sustained-release injection. The viscosity of the injection is 300cp-600cp (at 20℃-30℃). The release time of the sustained-release injection in vitro in physiological saline is 15-20 days, and the release time under the skin of mice is about 30-40 days.

Embodiment 2

[0107] The process of processing into a sustained-release injection is the same as in Example 1, but the difference is that the anti-tuberculosis active ingredient and its weight percentage are:

[0108] (1) 5-40% cycloserine, ofloxacin, ciprofloxacin or sparfloxacin;

[0109] (2) A combination of 5-40% cycloserine and 5-40% ofloxacin, ciprofloxacin or sparfloxacin;

[0110] (3) A combination of 5-40% ofloxacin and 5-40% ciprofloxacin or sparfloxacin; or

[0111] (4) A combination of 5-40% ciprofloxacin and 5-40% sparfloxacin.

Embodiment 3

[0113] Put 70mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 65000 into three containers (A), (B) and (C), and then add 100 ml of dichloromethane to each, dissolve and mix well , Add 30mg cycloserine, 30mg ciprofloxacin, 15mg cycloserine and 15mg ciprofloxacin to three containers respectively, shake well and spray dry to prepare 30% cycloserine, 30% ciprofloxacin, Microspheres for injection of 15% cycloserine and 15% ciprofloxacin. The dried microspheres were suspended in physiological saline containing 1.5% sodium carboxymethyl cellulose to prepare the corresponding suspension type sustained-release injection. The viscosity of the injection is 300cp-600cp (at 20℃-30℃). The release time of the sustained-release injection in vitro in physiological saline is 10-15 days, and the release time under the skin of mice is about 20-30 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to view more

Abstract

The slow released implanting agent and injection containing antituberculotic are set or injected to local tuberculosis focus for maintaining the local effective medicine concentration while lowing the systemic toxicity. The slow released injection consists of slow released microsphere and solvent. The slow released microsphere includes antituberculotic selected from Cycloserine, Ofloxacin, Ciprofloxacin and Sparfloxacin and slow releasing supplementary material, and the solvent is special solvent containing suspending agent. The suspending agent is carboxymethyl cellulose sodium, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released implanting agent may be prepared with slow released microsphere. The present invention has obvious and unique treating effect on various kinds of intractable tuberculosis.

Description

(1) Technical field [0001] The invention relates to a slow-release agent containing anti-tuberculosis drugs, which belongs to the technical field of medicines. Specifically, the present invention provides a sustained-release agent containing cycloserine and / or quinolone anti-tuberculosis drugs, which are mainly sustained-release injections and sustained-release implants. The sustained-release agent is mainly applied locally, which can obtain and maintain the effective drug concentration locally in the tuberculosis lesion. (2) Background technology [0002] Tuberculosis, represented by tuberculosis, is originally a disease that seriously affects people's health. It is widespread all over the world, killing hundreds of millions of people. It is called the white plague, and there was a saying of "ten tuberculosis and nine deaths". With the advent of antituberculosis drugs such as streptomycin, tuberculosis has become a treatable disease. However, with people neglecting its seriousne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/10A61K31/496A61K45/00A61K47/32A61K47/34A61K47/36A61K47/38A61K47/42A61P31/06
Inventor 孙忠厚
Owner JINAN KANGQUAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap